Studies on combination treatments of local therapy for oligometastasis are currently being conducted in NSCLC, which is primarily caused by specific gene mutations, including the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.